不同分期多原发肺癌对免疫治疗的病理反应并一例报告及文献复习
Pathologic Response to Immunotherapy in Different Stages of Multiple Primary Lung Cancer: A Case Report and Literature Review
DOI: 10.12677/ACM.2023.133714, PDF,   
作者: 魏超禹, 马世鑫：大连医科大学研究生院，辽宁 大连；王伦青*：青岛市市立医院胸外科，山东 青岛
关键词: 多原发肺癌；PD-1/PD-L1；免疫治疗；Multiple Primary Lung Cancer； PD-1/PD-L1； Immunotherapy
摘要: 目的：多原发肺癌的临床发病率逐年增长，给临床治疗带来了很大麻烦。本研究通过术后病理结果分析该疾病的临床特征，回顾性分析免疫治疗在该病中的治疗效果，旨在增加对该病的病理特征认识，促进疾病的全身性治疗。方法：报道1例多原发肺癌，并复习相关文献。结果：根据临床表现、CT检查及病理结果，诊断为多原发肺癌。结论：免疫治疗对分期较早的多原发肺癌不敏感，并非每个人都需要联合治疗以获得最佳疗效。
Abstract: Objective: The clinical incidence of multiple primary lung cancer is increasing year by year, which brings great trouble to clinical treatment. This study analyzed the clinical features of this disease by postoperative pathological results, and the therapeutic effects of immunotherapy in the disease were retrospectively analyzed in order to increase the understanding of the pathological features of the disease and promote the systemic treatment of the disease. Methods: A case of multiple primary lung cancer was reported and the related literatures were reviewed. Results: According to the clin-ical manifestations, CT examination and pathological findings, multiple primary lung cancers were diagnosed. Conclusion: Immunotherapy is not sensitive to multi primary lung cancer with early stage, and not everyone needs combination therapy for optimal outcome.
文章引用：魏超禹, 马世鑫, 王伦青. 不同分期多原发肺癌对免疫治疗的病理反应并一例报告及文献复习[J]. 临床医学进展, 2023, 13(3): 5036-5042. https://doi.org/10.12677/ACM.2023.133714

参考文献

[1] 陈双双, 马锐. 多原发癌的研究进展[J]. 癌症进展, 2019, 17(8): 883-886.
[2] Rostad, H., Strand, T.E., Naalsund, A., et al. (2008) Resected Synchronous Primary Malignant Lung Tumors: A Population-Based Study. The Annals of Thoracic Surgery, 85, 204-209. [Google Scholar] [CrossRef] [PubMed]
[3] Yu, Y.C., Hsu, P.K., Yeh, Y.C., et al. (2013) Surgical Results of Synchronous Multiple Primary Lung Cancers: Similar to the Stage-Matched Soli-tary Primary Lung Cancers? The Annals of Thoracic Surgery, 96, 1966-1974. [Google Scholar] [CrossRef] [PubMed]
[4] Chen, T.F., Xie, C.Y., Rao, B.Y., et al. (2019) Surgical Treatment to Multiple Primary Lung Cancer Patients: A Systematic Review and Meta-Analysis. BMC Surgery, 19, 185. [Google Scholar] [CrossRef] [PubMed]
[5] Shimada, Y., Saji, H., Otani, K., et al. (2015) Survival of a Surgi-cal Series of Lung Cancer Patients with Synchronous Multiple Ground-Glass Opacities, and the Management of Their Residual Lesions. Lung Cancer, 88, 174-180. [Google Scholar] [CrossRef] [PubMed]
[6] Li, R., Li, X., Xue, R., et al. (2018) Early Metastasis Detected in Patients with Multifocal Pulmonary Ground-Glass Opacities (GGOs). Thorax, 73, 290-292. [Google Scholar] [CrossRef] [PubMed]
[7] Su, K., Gao, S., Ying, J., et al. (2018) Sequencing a Super Multiple Synchronous Lung Cancer Reveals a Novel Variant in Driver Gene ARID1B. The Journal of Thoracic and Cardiovascular Surgery, 155, e185-e191. [Google Scholar] [CrossRef] [PubMed]
[8] Nikitas, J., DeWees, T., Rehman, S., et al. (2019) Stereotactic Body Radiotherapy for Early-Stage Multiple Primary Lung Cancers. Clinical Lung Cancer, 20, 107-116. [Google Scholar] [CrossRef] [PubMed]
[9] Chang, Y.L., Wu, C.T. and Lee, Y.C. (2007) Surgical Treatment of Synchronous Multiple Primary Lung Cancers: Experience of 92 Patients. The Journal of Thoracic and Cardiovascular Surgery, 134, 630-637. [Google Scholar] [CrossRef] [PubMed]
[10] Yang, H., Sun, Y., Yao, F., et al. (2016) Surgical Therapy for Bi-lateral Multiple Primary Lung Cancer. The Annals of Thoracic Surgery, 101, 1145-1152. [Google Scholar] [CrossRef] [PubMed]
[11] Zhao, L., Liu, C., Xie, G., Wu, F. and Hu, C. (2020) Multiple Primary Lung Cancers: A New Challenge in the Era of Precision Medicine. Cancer Management and Research, 12, 10361-10374. [Google Scholar] [CrossRef] 
[12] Viale, G., Trapani, D. and Curigliano, G. (2017) Mismatch Repair Deficiency as a Predictive Biomarker for Immunotherapy Efficacy. BioMed Research International, 2017, Article ID: 4719194. [Google Scholar] [CrossRef] [PubMed]
[13] Mok, T.S.K., Wu, Y.L., Kudaba, I., et al. (2019) Pembrolizumab versus Chemotherapy for Previously Untreated, PD-L1-Expressing, Locally Advanced or Meta-static Non-Small-Cell Lung Cancer (KEYNOTE-042): A Randomised, Open-Label, Controlled, Phase 3 Trial. The Lan-cet, 393, 1819-1830. [Google Scholar] [CrossRef] 
[14] Singal, G., Miller, P.G., Agarwala, V., et al. (2019) Association of Patient Characteristics and Tumor Genomics with Clinical Outcomes among Patients with Non-Small Cell Lung Cancer Using a Clinicogenomic Database. JAMA, 321, 1391-1399. [Google Scholar] [CrossRef] [PubMed]
[15] Umansky, V., Blattner, C., Fleming, V., et al. (2017) Mye-loid-Derived Suppressor Cells and Tumor Escape from Immune Surveillance. Seminars in Immunopathology, 39, 295-305. [Google Scholar] [CrossRef] [PubMed]
[16] 李瑛, 范忠义, 尤文叶, 杨俊兰, 焦顺昌. PD-1/PD-L1信号通路在肿瘤免疫逃逸中的作用及临床意义[J]. 解放军医学院学报, 2015, 36(7): 762-765.
[17] Alsaab, H.O., Sau, S., Alzhrani, R., et al. (2017) PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome. Frontiers in Pharmacology, 8, 561. [Google Scholar] [CrossRef] [PubMed]
[18] Zak, K.M., Kitel, R., Przetocka, S., et al. (2015) Structure of the Complex of Human Programmed Death 1, PD-1, and Its Ligand PD-L1. Structure, 23, 2341-2348. [Google Scholar] [CrossRef] [PubMed]
[19] Provencio, M., Nadal, E., Insa, A., et al. (2019) Neoadjuvant Chemo-Immunotherapy for the Treatment of Stage IIIA Resectable Non-Small-Cell Lung Cancer (NSCLC): A Phase II Multicenter Exploratory Study—Final Data of Patients Who Underwent Surgical Assessment. Journal of Clinical On-cology, 37, 8509-8509. [Google Scholar] [CrossRef] 
[20] Rusch, V., Chaft, J., Johnson, B., et al. (2018) Neoadju-vant Atezolizumab in Resectable Non-Small Cell Lung Cancer (NSCLC): Initial Results from a Multicenter Study (LCMC3). Journal of Clinical Oncology, 36, 8541-8541. [Google Scholar] [CrossRef] 
[21] Shihab, H.A., Rogers, M.F., Gough, J., et al. (2015) An Integrative Approach to Predicting the Functional Effects of Non-Coding and Coding Sequence Variation. Bioinformatics, 31, 1536-1543. [Google Scholar] [CrossRef] [PubMed]
[22] Schwarz, J.M., Cooper, D.N., Schuelke, M., et al. (2014) Muta-tionTaster2: Mutation Prediction for the Deep-Sequencing Age. Nature Methods, 11, 361-362. [Google Scholar] [CrossRef] [PubMed]
[23] Chen, H., Chong, W., Wu, Q., et al. (2019) Association of LRP1B Muta-tion with Tumor Mutation Burden and Outcomes in Melanoma and Non-Small Cell Lung Cancer Patients Treated with Immune Check-Point Blockades. Frontiers in Immunology, 10, 11-13. [Google Scholar] [CrossRef] [PubMed]
[24] Hsu, J., Hodgins, J.J., Marathe, M., et al. (2018) Contribution of NK Cells to Immunotherapy Mediated by PD-1/PD-L1 Blockade. Journal of Clinical Investigation, 128, 4654-4668. [Google Scholar] [CrossRef] 
[25] Daud, A.I., Loo, K., Pauli, M.L., et al. (2016) Tumor Immune Profiling Predicts Response to Anti-PD-1 Therapy in Human Melanoma. Journal of Clinical Investigation, 126, 3447-3452. [Google Scholar] [CrossRef] 
[26] Zhang, C., Zhang, J., Xu, F.P., et al. (2019) Genomic Landscape and Im-mune Microenvironment Features of Preinvasive and Early Invasive Lung Adenocarcinoma. Journal of Thoracic Oncol-ogy, 14, 1912-1923. [Google Scholar] [CrossRef] [PubMed]

为你推荐